ROKAE ROBOTICS (03752): Over-allotment option exercised in full; price stabilization period ends.
Leshi Robotics (03752) announced that the over-allotment option described in the prospectus was fully exercised by the global coordinators (on their own behalf and on behalf of the international underwriters) on August 5, 2026 (Wednesday), involving a total of 3.4547 million H shares, accounting for approximately 15.0% of the total number of shares available for subscription under the global offering (before any exercise of the over-allotment option). The over-allotment shares will be issued by the company at a price of HKD 38.00 per H share. The shares from the over-allotment option will be used to facilitate the delivery of part of the H shares to the recipients who have agreed to defer the delivery of the H shares they subscribed for under the global offering.
ROKAE ROBOTICS (03752) announced that the overall coordinator (acting on its own and on behalf of the international underwriters) has fully exercised the over-allotment option described in the prospectus on August 5, 2026 (Wednesday), involving a total of 3,454,700 H shares, accounting for approximately 15.0% of the total shares available for subscription under the global offering (prior to any exercise of the over-allotment option). The over-allotted shares will be allocated and issued by the company at HKD 38.00 per H share. The shares from the over-allotment option will be used to facilitate the delivery of a portion of H shares to those participants who have agreed to defer the delivery of the relevant H shares subscribed for under the global offering.
In addition, the stabilization period for the global offering ended on August 5, 2026 (Wednesday), which is the 30th day following the deadline for submitting applications for the Hong Kong public offering.
Related Articles
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.
US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.
LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.
US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.
LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
RECOMMEND
